2 ms·
Please read your own articles before posting. Your article it states clearly what the funding was for: > The goal of the initiative is the expansion of vaccine
by adriancr 6y ago
Please read your own articles before posting. Your article it states clearly what the funding was for:
> The goal of the initiative is the expansion of vaccine development and manufacturing capabilities in Germany, as well as the expansion of the number of participants in late-stage clinical trials.
- bildung 6y agoWhat you quoted is the shortend version of the goals of the funding program, here is a more complete description: https://www.bmbf.de/foerderungen/bekanntmachung-3035.html https://www.bmbf.de/foerderungen/bekanntmachung-3035.html The program is funding clinical trials 1 to 3, having bigger cohorts for trials 2 and 3, and scaling up production while trials are still in progress. In short: Everything that makes vaccine development expensive. Finding the actual vaccine candidates is the cheap part.
- adriancr 6y ago> Finding the actual vaccine candidates is the cheap part. Do you have any sources on that?
- bildung 6y agoSee here: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(18)30346-2/fulltext https://www.thelancet.com/journals/langlo/article/PIIS2214-1... Going from zero to preclinical is about 1/3 of the costs of going from preclinical to phase 2. Phase 3 is not part of this study, neither is parallel production.
- adriancr 6y agoThat is a study of existing vaccines based on existing practices (which result in astrazeneca's 70% effective vaccine) BioNTech is a different vaccine type, hence effectiveness and fact that both moderna and pfizer license it. The fact that Germany subsidised the last stages to speed it up doesnt mean technology should be public access. That's for the government and company to negotiate.